Global Prostate Cancer Therapeutics Market Size 2013-2017 | Forecast 2018-2024

22/mag/2018 12:23:06 sravan Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Prostate Cancer Therapeutics Market Size 2013-2017 | Forecast 2018-2024


Prostate is an exocrine gland and found only in males.  Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among the men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques.


Free sample of this report is available upon request @


Global prostate cancer therapeutics market is rapidly growing due to increase in incidence of prostate cancer and increase in ageing population. In addition, technological advancements in prostate cancer treatment such as radiation therapy and targeted therapy are expected to boost the prostate cancer therapeutics market. However, patients in underdeveloped and developing regions cannot afford the high costs of treatment and diagnosis of cancer can hinder market growth. In addition to this, low diagnostic rates due to unawareness about prostate cancer symptoms is hampering the prostate cancer therapeutics market.


 The global prostate cancer therapeutics market has been segmented-

1.      Drug class

·         Chemotherapeutic agents

·         Immune System Modulators

·         Hormones

·         Others


2.     Route of administration

·         Oral

·         Parenteral

·         Other

3.     End-users

Retail Pharmacy, hospital pharmacy and others.


Free TOC of this report is available upon request @



And lastly, on the basis of geographical regions the global prostate cancer drugs market has been segmented into following regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America expected to have major market share owing to increased research and development, developed healthcare infrastructure and high rate of prostate cancer incidents. In 2017, the American Cancer Society predicts that there will be around 161,360 new diagnoses of prostate cancer and that around 26,730 fatalities will occur because of prostate cancer in America alone. Europe is anticipated to grow at significant rates due to increase in prevalence rates and developed healthcare infrastructure facilities. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure facilities and increased research and development focused on cancer therapeutics.


Some of the key market players in prostate cancer drugs market include Johnson & Johnson Services Inc. (U.S.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), AstraZeneca (U.K), Ipsen Group (France), Sanofi (France), Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.), Bayer AG (Germany) Endo Pharmaceuticals, Inc. (U.S), and Pfizer, Inc (U.S.) to name a few. In 2016, USFDA approved a supplemental new drug application for XTANDI (Enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic Xastration resistance prostate cancer. And in 2011, Johnson & Johnson has received USFDA approval for ZytIGA used to treat metastatic prostate cancer


Ask Analyst for Full Information about this report @



New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early stage diagnosis. This, in turn, aids in increasing diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and market is highly competitive. Players adopting acquisitions, mergers and collaborations to strengthen product offerings in prostate therapeutics market. For instance, in 2017, Pfizer acquired Medivation, this acquisition represents opportunity to expand the business offering with an attractive pipeline and with Xtandi, medicine for men with prostate cancer. Moreover, in 2016, TESARO, Inc., an oncology-focused biopharmaceutical company, and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a global collaboration and license agreement focused on the development and commercialization of Niraparib specifically for the treatment of prostate cancer.


Get access to full summary @


About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX


Toll Free (US):+1-866-598-1553

Website @


blog comments powered by Disqus è un servizio offerto da Factotum Srl